Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefaan Rossenu

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Psychopharmacology (Oxford, England)|October 15, 2009
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophreniaJoris Berwaerts, Adriaan Cleton, Stefaan Rossenu, et al.
Clinical Pharmacokinetics|October 31, 2020
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant DepressionCarlos Perez-Ruixo, Stefaan Rossenu, Peter Zannikos, et al.
Clinical Pharmacokinetics|October 16, 2016
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with SchizophreniaMats O Magnusson, Mahesh N Samtani, Elodie L Plan, et al.
British Journal of Clinical Pharmacology|January 17, 2012
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromesXu Steven Xu, Kenneth Moore, Paul Burton, et al.
Journal of Pharmaceutical Sciences|September 27, 2014
Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteersFilippos Kesisoglou, Stefaan Rossenu, Colm Farrell, et al.
Journal of Clinical Pharmacology|August 29, 2009
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseSandra Boom, Krishna Talluri, Luc Janssens, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaStefaan Rossenu, Adriaan Cleton, David Hough, et al.
Blood|September 6, 2012
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraFilip Callewaert, Jan Roodt, Hans Ulrichts, et al.
Journal of Molecular Biology|May 16, 2006
Identification of the PXW sequence as a structural gatekeeper of the headpiece C-terminal subdomain foldWim Vermeulen, Marleen Van Troys, David Bourry, et al.
Journal of Clinical Pharmacology|March 29, 2014
A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaAdriaan Cleton, Stefaan Rossenu, Herta Crauwels, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Psychopharmacology (Oxford, England)|October 15, 2009
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophreniaJoris Berwaerts, Adriaan Cleton, Stefaan Rossenu, et al.
Clinical Pharmacokinetics|October 31, 2020
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant DepressionCarlos Perez-Ruixo, Stefaan Rossenu, Peter Zannikos, et al.
Clinical Pharmacokinetics|October 16, 2016
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with SchizophreniaMats O Magnusson, Mahesh N Samtani, Elodie L Plan, et al.
British Journal of Clinical Pharmacology|January 17, 2012
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromesXu Steven Xu, Kenneth Moore, Paul Burton, et al.
Journal of Pharmaceutical Sciences|September 27, 2014
Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteersFilippos Kesisoglou, Stefaan Rossenu, Colm Farrell, et al.
Journal of Clinical Pharmacology|August 29, 2009
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseSandra Boom, Krishna Talluri, Luc Janssens, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaStefaan Rossenu, Adriaan Cleton, David Hough, et al.
Blood|September 6, 2012
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraFilip Callewaert, Jan Roodt, Hans Ulrichts, et al.
Journal of Molecular Biology|May 16, 2006
Identification of the PXW sequence as a structural gatekeeper of the headpiece C-terminal subdomain foldWim Vermeulen, Marleen Van Troys, David Bourry, et al.
Journal of Clinical Pharmacology|March 29, 2014
A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaAdriaan Cleton, Stefaan Rossenu, Herta Crauwels, et al.
Pageof 3